What does the evidence say about Grape Sleep Quality Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Grape Sleep Quality Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - Severity, frequency and duration of migraine attacks, headache daily result (HDR), quality of life, migraine disability, mental health, anthropometric indices, blood pressure, and serum levels of calcitonin gene-related peptide (CGRP), vascular cell adhesion molecules-1, total antioxidant capacity, and malondialdehyde were measured at baseline and end of the trial. [Eshaghian N (2025); evidence level 2] - Conclusion This study provides evidence supporting the beneficial effects of GSE supplement on the serum levels of CGRP. [Eshaghian N (2025); evidence level 2] - Background The current study was conducted to assess the effect of grape seed extract (GSE) supplementation on inflammatory biomarkers, oxidative stress, clinical symptoms, and quality of life in migraine patients. [Eshaghian N (2025); evidence level 2] - Materials and methods In this randomized double-blinded controlled clinical trial, 50 patients with migraine were randomly allocated to receive either 200 mg/day GSE supplement ( n = 25) or placebo ( n = 25) for 8 weeks. [Eshaghian N (2025); evidence level 2] - Polyphenols strengthen the intestinal barrier and reduce endotoxemia; cocoa bean shell extracts protected against oxysterol‐induced intestinal damage and improved gut microbiota composition in preclinical models (Alia et al. ). [Akif Adnan (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.